dactinomycin has been researched along with irinotecan in 20 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (10.00) | 18.2507 |
| 2000's | 8 (40.00) | 29.6817 |
| 2010's | 7 (35.00) | 24.3611 |
| 2020's | 3 (15.00) | 2.80 |
| Authors | Studies |
|---|---|
| Akiyama, S; Baba, M; Furukawa, T; Nitanda, T; Okamoto, M; Sugimoto, Y; Wang, X | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chen, X; Lin, X; Skolnik, S; Wang, J | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Kanematsu, T; Kawanami, K; Kohno, K; Kuwano, M; Taniguchi, K; Wada, M | 1 |
| Kato, M; Suzuki, A | 1 |
| Suzuki, A; Tsutomi, Y | 1 |
| Morikawa, Y | 1 |
| Breitfeld, P; Crews, KR; Donaldson, SS; Houghton, P; Lyden, E; Meyer, WH; Pappo, AS; Parham, D; Wiener, E | 1 |
| Abe, T; Goto, J; Hishinuma, T; Kobayashi, M; Mano, N; Okada, M; Takeuchi, T; Unno, M; Yamaguchi, H | 1 |
| Hayashi, Y; Hirato, J; Kuroiwa, M; Park, MJ; Sakamoto, J; Shimada, A; Sotomatsu, M; Suzuki, N | 1 |
| Pappo, A; Paulino, AC | 1 |
| Kumabe, T; Niizuma, H; Osawa, S; Saito, R; Sonoda, Y; Tominaga, T; Watanabe, M | 1 |
| Kamimura, S; Kinoshita, M; Miyachi, M; Moritake, H; Sawa, D; Yamada, A | 1 |
| Arndt, CA; Casey, DL; Chi, YY; Donaldson, SS; Gupta, AA; Hawkins, DS; Lautz, TB; Rodeberg, DA; Routh, JC; Tian, J; Wolden, SL; Yock, TI | 1 |
| Hara, J; Hosoi, H; Hosono, A; Kikuta, A; Koh, K; Miyachi, M; Ogawa, A; Teramukai, S; Tsuchiya, K | 1 |
| Alessandro, O; Bergamaschi, L; Casanova, M; Chiaravalli, S; Diletto, B; Ferrari, A; Giandini, T; Livellara, V; Pecori, E; Sironi, G | 1 |
| Ghaedi, K; Majd, A; Miralaei, N; Peymani, M; Safaei, M | 1 |
| Alsherbiny, MA; Bhuyan, DJ; Chang, D; Li, CG; Low, MN | 1 |
2 review(s) available for dactinomycin and irinotecan
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
[Childhood rhabdomyosarcoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Child; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Dactinomycin; Humans; Irinotecan; Radiotherapy Dosage; Rhabdomyosarcoma; Risk; Vincristine | 2005 |
2 trial(s) available for dactinomycin and irinotecan
| Article | Year |
|---|---|
Two consecutive phase II window trials of irinotecan alone or in combination with vincristine for the treatment of metastatic rhabdomyosarcoma: the Children's Oncology Group.
Topics: Adolescent; Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Dactinomycin; Drug Administration Schedule; Female; Humans; Infant; Irinotecan; Male; Neoplasm Metastasis; Rhabdomyosarcoma; Treatment Outcome; Vincristine | 2007 |
Phase II study of vincristine, actinomycin-D, cyclophosphamide and irinotecan for patients with newly diagnosed low-risk subset B rhabdomyosarcoma: A study protocol.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Clinical Protocols; Cyclophosphamide; Dactinomycin; Humans; Irinotecan; Neoplasm Staging; Rhabdomyosarcoma; Treatment Outcome; Vincristine | 2019 |
16 other study(ies) available for dactinomycin and irinotecan
| Article | Year |
|---|---|
Breast cancer resistance protein (BCRP/ABCG2) induces cellular resistance to HIV-1 nucleoside reverse transcriptase inhibitors.
Topics: Anti-HIV Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; CD4-Positive T-Lymphocytes; Cells, Cultured; Doxorubicin; Drug Resistance, Neoplasm; Drug Resistance, Viral; HIV Reverse Transcriptase; HIV-1; Humans; Indoles; Lamivudine; Microbial Sensitivity Tests; Neoplasm Proteins; Reverse Transcriptase Inhibitors; Zidovudine | 2003 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
Topics: Adenosine; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Sub-Family B Member 4; ATP-Binding Cassette Transporters; Biological Transport; Caco-2 Cells; Chromatography, Liquid; Dibenzocycloheptenes; Diketopiperazines; Drug Discovery; Heterocyclic Compounds, 4 or More Rings; Humans; Intestinal Absorption; Mass Spectrometry; Models, Biological; Neoplasm Proteins; Pharmaceutical Preparations; Predictive Value of Tests; Propionates; Quinolines; Substrate Specificity | 2011 |
Drug-induced down-regulation of topoisomerase I in human epidermoid cancer cells resistant to saintopin and camptothecins.
Topics: Antibiotics, Antineoplastic; Benz(a)Anthracenes; Camptothecin; Carcinoma, Squamous Cell; Dactinomycin; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Drug Resistance, Neoplasm; Enzyme Induction; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; KB Cells; Neoplasm Proteins; RNA, Messenger; RNA, Neoplasm; Topoisomerase I Inhibitors; Tumor Cells, Cultured | 1996 |
Chemotherapeutic agent CPT-11 induces the new expression of the apoptosis initiator to the cytoplasm.
Topics: Amino Acid Sequence; Animals; Apoptosis; Camptothecin; Carcinoma, Hepatocellular; Caspase 1; Cell Extracts; Cell Nucleus; Cycloheximide; Cysteine Endopeptidases; Cysteine Proteinase Inhibitors; Cytoplasm; Dactinomycin; DNA; Humans; Irinotecan; Liver; Liver Neoplasms; Male; Molecular Sequence Data; Oligopeptides; Protein Synthesis Inhibitors; Rats; Tumor Cells, Cultured | 1996 |
Inductions of fibroblast-like morphology and high growth activity by low-dose CPT-11 in PC12 cells: role of tenascin.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Carboxylic Acids; Caspase Inhibitors; Caspases; Cell Division; Cell Nucleus; Cell Survival; Cell Transformation, Neoplastic; Culture Media, Conditioned; Dactinomycin; DNA Fragmentation; Dose-Response Relationship, Drug; Enzyme Inhibitors; Fibroblasts; Fumonisins; Irinotecan; Oligopeptides; PC12 Cells; Rats; Tenascin; Tumor Necrosis Factor-alpha | 2000 |
Rapid screening of antineoplastic candidates for the human organic anion transporter OATP1B3 substrates using fluorescent probes.
Topics: Antineoplastic Agents; Camptothecin; Chenodeoxycholic Acid; Dactinomycin; Docetaxel; Fluorescent Dyes; Humans; Irinotecan; Kinetics; Lysine; Mitoxantrone; Organic Anion Transporters, Sodium-Independent; Paclitaxel; Signal Processing, Computer-Assisted; Solute Carrier Organic Anion Transporter Family Member 1B3; Spectrometry, Fluorescence; Taxoids; Transfection | 2008 |
Manifestation of alveolar rhabdomyosarcoma as primary cutaneous lesions in a neonate with Beckwith-Wiedemann syndrome.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Beckwith-Wiedemann Syndrome; Bone Marrow Transplantation; Camptothecin; Cyclophosphamide; Dactinomycin; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Infant, Newborn; Irinotecan; Potassium Channels, Voltage-Gated; Rhabdomyosarcoma, Alveolar; Skin Neoplasms; Transcription, Genetic; Vincristine | 2009 |
Alveolar rhabdomyosarcoma of the extremity and nodal metastasis: Is the in-transit lymphatic system at risk?
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Camptothecin; Child; Combined Modality Therapy; Cyclophosphamide; Dacarbazine; Dactinomycin; Etoposide; Fatal Outcome; Female; Foot; Groin; Humans; Ifosfamide; Irinotecan; Lymph Node Excision; Lymphatic Metastasis; Lymphatic System; Male; Niacinamide; Phenylurea Compounds; Pyridines; Radiotherapy, Adjuvant; Radiotherapy, High-Energy; Rhabdomyosarcoma, Alveolar; Salvage Therapy; Soft Tissue Neoplasms; Sorafenib; Temozolomide; Thigh; Vincristine | 2009 |
Infratentorial brain metastases of pediatric non-epithelial malignant tumors: three case reports.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Carboplatin; Chemotherapy, Adjuvant; Child; Child, Preschool; Cisplatin; Combined Modality Therapy; Dactinomycin; Doxorubicin; Etoposide; Humans; Ifosfamide; Infant; Infratentorial Neoplasms; Irinotecan; Melphalan; Neoplasm Metastasis; Neuroblastoma; Rhabdomyosarcoma; Thiotepa; Topotecan; Vincristine | 2011 |
Successful treatment of metastatic alveolar rhabdomyosarcoma with MGMT gene promoter methylation by temozolomide-based combination chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoradiotherapy; Child, Preschool; Cyclophosphamide; Dacarbazine; Dactinomycin; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; DNA, Neoplasm; Humans; Irinotecan; Male; MicroRNAs; Neoplasm Metastasis; Promoter Regions, Genetic; Rhabdomyosarcoma, Alveolar; RNA, Neoplasm; Temozolomide; Tumor Suppressor Proteins; Vincristine | 2018 |
Increased local failure for patients with intermediate-risk rhabdomyosarcoma on ARST0531: A report from the Children's Oncology Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Child; Child, Preschool; Cyclophosphamide; Dactinomycin; Extremities; Female; Head and Neck Neoplasms; Humans; Infant; Infant, Newborn; Irinotecan; Male; Radiotherapy; Randomized Controlled Trials as Topic; Retroperitoneal Neoplasms; Rhabdomyosarcoma; Risk; Treatment Failure; Urinary Bladder Neoplasms; Vincristine; Young Adult | 2019 |
Multiagent chemotherapy including IrIVA regimen and maintenance therapy in the treatment of desmoplastic small round cell tumor.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Cyclophosphamide; Dactinomycin; Desmoplastic Small Round Cell Tumor; Dose-Response Relationship, Drug; Doxorubicin; Humans; Ifosfamide; Irinotecan; Male; Treatment Outcome; Vincristine; Vinorelbine; Young Adult | 2022 |
Integrated pan-cancer of AURKA expression and drug sensitivity analysis reveals increased expression of AURKA is responsible for drug resistance.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aurora Kinase A; Azepines; Benzodioxoles; Biomarkers, Tumor; Camptothecin; Cell Line, Tumor; Chromones; Dactinomycin; Datasets as Topic; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Morpholines; Neoplasms; Prognosis; Pyridines; Triazoles | 2021 |
Synergistic Interactions of Cannabidiol with Chemotherapeutic Drugs in MCF7 Cells: Mode of Interaction and Proteomics Analysis of Mechanisms.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cannabidiol; Cell Line, Tumor; Cell Survival; Dactinomycin; Docetaxel; Doxorubicin; Drug Screening Assays, Antitumor; Drug Synergism; Female; Humans; Irinotecan; MCF-7 Cells; Paclitaxel; Proteome; Proteomics; Vinorelbine | 2021 |